Condition
Alloimmunization
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07607197Phase 1Recruiting
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
NCT07414511Recruiting
Hemophilia A Research Program
NCT03288012UnknownPrimary
Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Showing all 3 trials